4D Molecular Therapeutics, Inc. NMS · FDMT

4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population

GlobeNewswire Inc. · 17h ago

4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules Capital

GlobeNewswire Inc. · 20d ago

Age-related Macular Degeneration Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 90+ Leading Players Wheeling the Therapeutics Landscape

GlobeNewswire Inc. · 30d ago

4DMT to Participate in Upcoming Investor Conferences

GlobeNewswire Inc. · 149d ago

4DMT Appoints Kristian Humer as Chief Financial Officer

GlobeNewswire Inc. · 244d ago

4DMT Announces Exclusive License Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of 4D-150 in Asia-Pacific

GlobeNewswire Inc. · 261d ago

GenVivo Strengthens Oncology Leadership with Appointment of Noriyuki Kasahara, M.D., Ph.D., as Chief Scientific Officer

GlobeNewswire Inc. · 311d ago

4dMT Revenue Jumps 200 Percent in Q2

The Motley Fool · 342d ago

4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

GlobeNewswire Inc. · 342d ago

4DMT Announces Presentations at 43rd Annual Scientific Meeting of the American Society of Retina Specialists

GlobeNewswire Inc. · 360d ago

Gene Therapy in Ophthalmology Industry Report 2025-2035: Global Market Poised for Growth as Inherited Retinal Disease Cases Surge Worldwide

GlobeNewswire Inc. · 438d ago

2025 Market Prospects of Adeno-Associated Virus Vectors in Gene Therapy Pipeline: 200 Pipeline Drugs and the Strategic Workings of 180+ Companies

GlobeNewswire Inc. · 501d ago

Cell and Gene Therapies in Rare Disorders Market to Skyrocket Across the 7MM During the Forecast Period (2025–2034) | DelveInsight

GlobeNewswire Inc. · 512d ago

4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program

GlobeNewswire Inc. · 525d ago

FDMT Investors Have Opportunity to Join 4D Molecular Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm

Benzinga · 674d ago

4DMT to Participate in the 2024 Cantor Global Healthcare Conference

GlobeNewswire Inc. · 684d ago

4d Molecular Therapeutics CEO sells $290k in stock - Investing.com

Investing.com · 736d ago

Assessing 4D Molecular Therapeutics: Insights From 7 Financial Analysts

Benzinga · 752d ago

4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting

GlobeNewswire Inc. · 770d ago

Goldman Sachs Optimistic About Regenxbio's Gene Therapy Pipeline, Sees Over 160% Upside

Benzinga · 771d ago

Analyst Expectations For 4D Molecular Therapeutics's Future

Benzinga · 771d ago

4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Modulator-Ineligible/-Intolerant Cystic Fibrosis at 47th European Cystic Fibrosis Conference

GlobeNewswire Inc. · 773d ago

4D Molecular Therapeutics, Inc. (FDMT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Zacks Investment Research · 808d ago

To The Moon! A Look Inside An ETF Focused On Companies At The Cutting Edge Of Innovation

Benzinga · 821d ago

4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis

GlobeNewswire Inc. · 843d ago